Latest Reagents News

Link Technologies Announces Partnership with American International ChemicalLink Technologies Ltd has announced that it will partner with American International Chemical (AIC) to distribute Link-branded products in North America. AIC will offer a sub-set of Link’s specialist oligonucleotide reagents, focusing on the bulk m...

Transgenomic Acquires Clinical Sample Biorepository from Gene LogicTransgenomic, Inc. (OTCBB: TBIO) today announced it has entered into an agreement with Gene Logic, Inc., an Ocimum Biosolutions Company, to acquire its biorepository assets for $250,000 in cash. The biorepository contains thousands of human biological samples that can be used to validate diagnostic assays developed by Transgenomic. Transgenomic will use th...

False claims that GM protein Bt is present in mothers' blood and foetus tissues are based on incompetent chemical analysis

In 2011 a paper was published by some Canadian workers examining agricultural pesticide residues in the newborn babies and mothers.This protein, generally called Bt and also called Cry is present in genetically manipulated crops, and also in biological pesticides used by organic farmers.the claims about its presence in maternal tissues are highly disputed and controversial .They are however repeat...

AbD Serotec launches new HuCAL antibodies for development of novel antibody therapeuticsAbD Serotec, MorphoSys AG’s division for research and diagnostic antibodies, is to launch a series of novel anti-drug antibodies (ADAs) as diagnostic reagents. Starting with the recent launch of fully human, recombinant antibodies binding Rituximab...

Link Technologies in oligonucleotides partnership with American International ChemicalUK-based oligonucleotide reagent manufacturer Link Technologies Ltd has formed a partnership with American International Chemical in which AIC will distribute Link-branded products in North America. AIC will offer part of Link’s specialist oligonuc...

BD Issues 2011 Sustainability ReportFRANKLIN LAKES, N.J., May 23, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today the publication of its 2011 Sustainability Report. The report focuses on the Company's shared-value approach to sustainability, which focuses on the relationship among strong economic performance, social responsibility and...

AbD Serotec to Launch Panel of HuCAL Anti-Drug Antibodies Supporting the Development of Novel Antibody TherapeuticsMorphoSys AG / AbD Serotec to Launch Panel of HuCAL Anti-Drug Antibodies Supporting the Development of Novel Antibody Therapeutics . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. New Product Category Targets Contract Research Organizations and Pharmaceutical CompaniesMorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX)...

Panel of HuCAL Anti-Drug Antibodies to be launched by AbD SerotecMorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its division for research and diagnostic antibodies, AbD Serotec, will launch a series of novel anti-drug antibodies (ADAs) to strengthen its position as a leading provider...

Deals Shaping The Medical Industry, May 2012The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceut...

BD Appoints CEO Vincent A. Forlenza as Chairman of the BoardFRANKLIN LAKES, N.J., May 22, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Chief Executive Officer and President Vincent A. Forlenza will assume additional responsibility as Chairman of the Board, effective July 1, 2012, following his appointment by the Board of Directors. Mr. Forlenza will succeed...

New Website Reflects Strategic FocusSurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic (IVD) technologies to the healthcare industry, is pleased to announce the launch of its new website, www.surmodics.com. The website, revealed earlier this year, reflects SurModics' strategic focus on its two core businesses: Me

Investigators describe how they synthesized polymers to stabilize proteinsProteins are widely used as drugs - insulin for diabetics is the best known example - and as reagents in research laboratories, but they react poorly to fluctuations in temperature and are known to degrade in storage.

IVAX Diagnostics, Inc. Reports First Quarter 2012 Financial ResultsIVAX Diagnostics, Inc. (NYSE Amex: IVD), a fully integrated in vitro diagnostics company, reports its financial results for the quarter ended March 31, 2012. Kevin D. Clark, Chief Executive Officer, Chief Operating Officer and President of IVAX Diagnostics, said, “I am pleased to report a continuation in the first quarter of 2012 of the turnarou...

AB SCIEX Expands Its iChemistry™ Solutions Portfolio With Sensitivity-enhancing Reagents for Mass SpectrometryAB Sciex Pte. Ltd., a global leader in life science analytical technologies, today announced the commercial availability of Amplifex™ Reagents, the first of a new family of advanced chemistries designed to boost the performance of mass spectrometers, improve data precision and significantly increase sensitivity beyond conventional limits. The new reagen...

AB SCIEX Launches the World’s Most Sensitive Mass Spectrometer to Achieve the Lowest Limits of Quantitation in Complex MatricesAB SCIEX, a global leader in life science analytical technologies, today announced the introduction of the AB SCIEX 6500 series. The new AB SCIEX Triple Quad™ 6500 and QTRAP® 6500 systems are next-generation mass spectrometers that deliver up to a 10x increase in sensitivity over the best-selling, high-performance triple quadrupole system on the...

GenDx obtains world wide distribution rights of QIAGEN® LongRange PCRPerformance of GenDx SBTexcellerator® Reagents for tissue typing diagnostics in combination with...

BD and Heart to Heart International Collaborate on Second Volunteer Service Trip to Help Improve Healthcare in HaitiFRANKLIN LAKES, N.J. and OLATHE, Kan., May 21, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Heart to Heart International, a humanitarian medical aid nonprofit organization, are teaming up for their second joint volunteer initiative to strengthen healthcare in Haiti. A team of 16 BD employees from around the world w...

Transgenomic Announces CE IVD Mark for the WAVE MCE System and SURVEYOR® Scan KRAS Kit in EuropeTransgenomic, Inc. (OTCBB: TBIO) today announced it has achieved CE IVD Mark registration in Europe for the diagnostic use of its proprietary WAVE MCE System and SURVEYOR® Scan KRAS Kit. Analysis of the KRAS gene is critical for treatment decision-making in many cancer types. Gaining the CE IVD Mark enables diagnostic product sales in countries in the Eur...

Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patientsTUCSON, Ariz., May 21, 2012 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced today that it has co-exclusively sub-licensed certain patents and patent applications from Gen-Probe Incorporated (GPRO) for the worldwide in vitro diagnostic (IVD) rights for measuring ERG protein expression through immunohistochemistry (IHC) in prostate tissue. T...

Girindus, Marina Biotech in Marketing PactGirindus to develop oligonucleotide reagents

BellBrook Labs Launches More Sensitive Transcreener® Assay for GlycosyltransferasesBellBrook Labs, a leader in high throughput screening assays for drug discovery, announced the launch of a new, more sensitive version of their Transcreener UDP2 Assay for glycosyltransferases and other UDP-producing enzymes. The new glycosyltransferase assay will better serve a growing interest in targeting protein glycosylation as a novel therapeutic approach for cancer and other debilitating di...

Bioo Scientific Releases Improved Kits for Directed Drug DeliveryAustin, TX, May 18, 2012 --(PR.com)-- While it has been eleven years since the demonstration that sequence specific, small, synthetic, double stranded ribonucleic acids were shown to induce gene specific silencing in mammalian cells, delivery formulations that supply a metered dose of RNAi agent to the desired target site in a cost efficient fashion are still needed. Bioo Scientific has made adv...

Agilent to Acquire Dako for $2.2 BillionAgilent Technologies Inc. (NYSE:A) and EQT, the Sweden-based private equity group, today announced the execution of a definitive agreement for Agilent to acquire Dako, the Denmark-based cancer diagnostic company. The $2.2 billion acquisition (on a debt-free basis) is the largest in Agilent’s history. “In the rapidly growing diagnostics market,...

ARUP Laboratories celebrates new state-of-the-art diagnostic technology with the VENTANA BenchMark Special Stains systemTUCSON, Ariz., May 17, 2012 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced the unveiling of its new state-of-the-art BenchMark Special Stains system during a ribbon-cutting ceremony at ARUP (Associated Regional and University Pathologists) Laboratories in Salt Lake City, Utah. Built on its industry-leading VENTANA BenchMark technology, the new Ben...

Agilent to acquire Dako for $2.2BAgilent Technologies Inc. (NYSE:A) will acquire cancer diagnostic and tools company Dako A/S (Glostrup, Denmark) for $2.2 billion in cash. Agilent said the acquisition will increase its presence in the life sciences and diagnostic markets, and comple...

0 1 2 3 4 ›»

buy Reagents market research data and corporate reports now Advertisement